

Curriculum Vitae

Leslie Oleksowicz, M.D.

Date Prepared: 03/01/2022

Name: Leslie Oleksowicz, M.D.

Home Address: 2627 Stonehaven Drive
Cincinnati, OH 45245

Phone: HOME: 513-620-8685; Cell: 513-403-2650

Email: leslie.oleksowicz@gmail.com
loleksowicz@earthlink.net

Place of Birth & Ware, MA 01082

Citizenship U.S Citizen

Education

9/1974 - 6/1978	BA Magna Cum Laude Phi Beta Kappa	Biology	Amherst College Amherst, Massachusetts
9/1978 - 6/1982	MD	Medicine	Tufts University School of Medicine Boston, Massachusetts

Postdoctoral Training

7/1982-7/1985	Residency	Internal Medicine	Montefiore Hospital/ Albert Einstein College of Medicine, Bronx, New York
7/1985-7/1987	Fellowship	Hematology	Mount Sinai Medical Center, New York, New York
7/1987-7/1989	Fellowship	Medical Oncology	Mount Sinai Medical Center, New York, New York.

Current Employment

1/2015-present	Leslie Oleksowicz, M.D, LLC, Consultant	8190-A Beechmont Ave, Suite 175 Cincinnati, OH 45255-6177
----------------	---	--

Faculty Academic Appointments

7/1989-11/1991	Instructor	Medical Oncology	Mount Sinai Medical Center, New York, New York
6/1992-7/1998	Assistant Professor of Medicine	Medical Oncology	Montefiore Hospital/ Albert Einstein College of Medicine Bronx, New York
9/1998-7/2003	Associate Professor of Medicine	Medical Oncology	Roswell Park Cancer Institute Buffalo, New York
9/2003-5/2012	Associate Professor of Medicine	Hematology/Oncology	University Hospital/University of Cincinnati Cincinnati, Ohio
8/2012-4/2013	Professor of Medicine	Hematology/Oncology	Saint Louis University Medical Center, Saint Louis, Missouri
9/16/2013- 12/31/2014	Attending Clinician	Hematology/Oncology	<u>Dana Farber Cancer Institute</u> Boston, Massachusetts

Appointments at Hospitals/Affiliated Institutions

7/1989-11/1991	Clinical Assistant	Medical Oncology	Mount Sinai Medical Center
6/1992-7/1998	Assistant Attending	Medical Oncology	Montefiore Hospital
9/1998-7/2003	Associate Attending	Internal Medicine/Medical Oncology	Roswell Park Cancer Institute
9/2003-5/2012	Associate Attending	Internal Medicine/Medical Oncology	University Hospital, University of Cincinnati
9/2003-5/2012	Associate Attending	Internal Medicine/Medical Oncology	University Point Practice, Satellite facility of University of Cincinnati, West Chester, OH
12/2004-6/2010	Courtesy Associate Attending	Internal Medicine/Medical Oncology	Christ Hospital, Cincinnati, OH
9/2003-5/2012	Associate Attending	Internal Medicine/Medical Oncology	West Chester Medical Center, West Chester, OH (hospital owned by University of Cincinnati)
4/2009-5/2012	Associate Attending	Internal Medicine/Medical Oncology	University Point Surgical Hospital, West Chester, OH
8/2012-4/2013	Attending Professor	Internal Medicine/Medical Oncology	Saint Louis University Hospital
9/2013-12/2014	Faculty Clinician	Medical Oncology	Dana Farber Cancer Institute Boston, MA
9/2013-12/2014	Clinician	Hematology/Oncology	Lawrence and Memorial/Dana Farber Community Cancer Center, Waterford, CT Lawrence and Memorial Hospital, New London, CT

Current Licensure

1985	New York (active)	#158402-1
2003	Ohio (active)	#35-083335
2012	Missouri (inactive)	#2012021332
2013	Connecticut (inactive)	#052051

Certification

10/1987	Board Certified Diplomat in Internal Medicine
8/1989	Board Certified Diplomat in Medical Oncology

Other Professional Positions

1/1997-3/1997	Consultant	Merck Pharmaceutical: Evaluation of clinical and laboratory data related to COX-2 inhibitor.
10/1996-3/1998	Course Director	Practical Reviews in Cancer Management. Monthly review of recent clinical studies in medical oncology
8/2002-6/2012	Advisory Board Member	National Kidney Cancer Association
6/10/2006	Course Director	Mid-West Leukemia Symposium
7/22/2006	Course Director	First Annual University of Cincinnati Genitourinary Symposium
9/2007-9/2008	Advisory Board Member	Novartis (Interleukin-2)
7/2007-9/2008	Course Director	Second Annual University of Cincinnati Genitourinary Symposium
9/2007-9/2008	Member speaker bureau	Bayer/Onyx
2/2008-5/2012	Advisory Board Member	Association of Community Cancer Center
7/26/2008	Course Director	Third Annual University of Cincinnati Genito-Urinary Symposium
8/2008-4/2013	Principal Investigator of SWOG	University of Cincinnati and University of Saint Louis
9/2009-10/2010	Advisory Board Member	Pfizer
7/26/2009	Course Director	Fourth Annual University of Cincinnati Genitourinary Symposium
6/2011-6/2012	Advisory Board Member	Centacore-Ortho

Major Administrative Leadership Positions

Local

9/1998-7/2003	Director of GU Oncology	Roswell Park Cancer Institute
9/1998-7/2003	Director of Melanoma and Sarcoma Oncology	Roswell Park Cancer Institute

9/1998-7/2003	Director of High Dose IL-2 Service	Roswell Park Cancer Institute
7/2003-5/2012	Director of GU Oncology	University of Cincinnati Medical Center
7/2003-5/2012	Director of Melanoma and Sarcoma Oncology	University of Cincinnati Medical Center
7/2003-5/2012	Director of High Dose IL-2 Service	University of Cincinnati Medical Center
11/2003-6/2009	Co-Director Leukemia Services	University of Cincinnati Medical Center
8/2012-4/2013	Director GU Services	University of Saint Louis Medical Center
8/2012-4/2013	Director of Melanoma/Sarcoma Services	University of Saint Louis Medical Center

Committee Service

Local

9/1992-6/1998	Transfusion Committee 9/92-6/1998	Montefiore Hospital/Albert Einstein College of Medicine Member
9/1995-6/1998	Cancer Center Protocol Review Committee 9/1995-6/1998	Albert Einstein Cancer Center Vice Chair
9/1995-6/1998	Cancer Center Protocol Audit Committee 9/1995-6/1998	Albert Einstein Cancer Center Coordinator
9/1992-6/1998	Hematology Malignancy Working Group 9/1992-6/1998	Montefiore Hospital/Albert Einstein Member
9/1992-6/1998	Breast Malignancy Affinity Group 9/1992-6/1998	Member Montefiore Hospital/Albert Einstein
10/1998-10/1999	CME Advisory Board 10/1998-10/1999	Roswell Park Cancer Institute Member
5/1999-6/2000	Morbidity and Mortality Committee 5/1999-6/2000	Roswell Park Cancer Institute Member
5/1999-6/2000	Quality Improvement Committee 5/1999-6/2000	Roswell Park Member
1/2001-1/2002	IRB 1/2001-1/2002	Roswell Park Member
9/2003-4/2012	Hematology/Oncology Grand Rounds 9/2003-4/2012	University of Cincinnati Director, Coordinator and Master of Ceremonies
9/2003-5/2006	Scientific Review Protocol Committee 9/2003-5/2006	University of Cincinnati Member
9/2004-6/2006	Ethics Committee 9/2004-6/2006	University of Cincinnati Co-Chair
9/2003-8/2008	Hematology/Oncology Clinical Research Forum 9/2003-8/2008	University of Cincinnati Director
9/2004-7/2007	LEUKEMIA Affinity Group 9/2004-7/2007	University of Cincinnati Member
5/2008-5/2012	Medical Center Fund of Cincinnati 5/2008-5/2012	University of Cincinnati Member

Regional

1985-1987	Society for the Study of Blood	Teaching Hospitals in the Greater New York Area Member
-----------	--------------------------------	---

National and International

11/002-11/2003	Advisory Board on Cancer Related Fatigue 11/2002-11/2003	NCCN Member
8/2002-present	Advisory board 8/2002-present	National Kidney Cancer Association Member

Professional Societies

1/1990-9/2012	American Society of Hematology 1/1990-9/2003	Member
1996-present	American Society of Clinical Oncology 1996-present	Member
9/1998-6/2003	Cancer and Leukemia B (CALGB)	Member

6/1992-7/1998	9/1998-6/2003 Eastern cooperative Group (ECOG) 6/1992-7/1998	Member
1985-present	Phi Delta Epsilon Fraternity 1985-present	Member
1982-1987	American College of Physicians 1982-1987	Member
8/2002-present	National Kidney Cancer Association 8/2002-present	Member, Editorial Advisory Board
10/2003-4/2013	SWOG	Member

Editorial Activities

Cancer
Transfusion
Southern Journal of Medicine
Journal of Urology
American Journal of Medical Sciences

Other Editorial Roles

2009-present Editorial Advisory Board Kidney Cancer

Honors and Prizes

6/1978	Webster Prize	Amherst College	Undergraduate Thesis
9/1978-9/1982	Simpson Fellowship	Tufts University School of Medicine	Scholarship based on GPA
9/1978-9/1982	Hampden Scholarship	Tufts University School of Medicine	Scholarship based on GPA
2/1997	Third Prize awarded at basic investigators research symposium	Albert Einstein college of Medicine	Third prize for best scientific paper
11/2002	Certificate of recognition	Roswell Park	Excellence in clinical practice

Report of Funded and Unfunded Projects

Funding Information

Past

1/1999-6/2003	A Phase II Pilot Study of Dose –Intensive IL-2, DTIC and IFN in Patients with Metastatic Malignant Melanoma. Leslie Oleksowicz, P.I. ; \$60,000 from Schering Pharmaceuticals
1/1999-6/2003	A Phase II Study of Dose-Intensive IL-2 by IV Bolus and Low Dose Immunomodulating IFN as Therapy for Patients with Metastatic or Unresectable RCC. Leslie. Oleksowicz, P.I. Investigator-initiated. \$40,000 from Schering Pharmaceuticals
1/1999-6/2003	An adjuvant Dose-intensive Trial of High Dose bolus IL-2 in Patients with High Risk Renal Cell Carcinoma. Leslie. Oleksowicz, P.I. Investigator Initiated. \$20,000 from Chiron Pharmaceuticals
1/1999-6/2003	A Phase II Study of Post-Transurethral Resection M-VAC and Taxol/Gemcitabine Chemotherapy in Patients with Invasive Transitional Cell Bladder Cancer. Leslie Oleksowicz, P.I. \$50,000 from Bristol Pharmaceuticals.
1/2003-6/2004	A Phase II Trial Investigating the Efficacy of High Dose-Intensive IL-2 in Combination with Capecitabine in Patients with Stage IV Renal Cell Carcinoma. Leslie Oleksowicz, P.I. \$75,000 from Roche Pharmaceuticals.
04/2005-5/2006	A Phase II Trial of Fludarabine and High Dose Bolus Interleukin-2 in Patients with Stage IV or Surgically Unresectable Renal Cell Carcinoma. Leslie Oleksowicz, P.I. Investigator-initiated; \$150,000 from Chiron.
04/2005	A Phase II Trial of Taxotere, Gleevec, Complete Androgen Blockade and Zometa in Patients with a Rising PSA s/p Definitive Treatment. Leslie Oleksowicz, P.I. Investigator-Initiated. \$120,000 from Novartis
7/1992-7/1993	The Role of IL-6 on Platelet Function. Leslie Oleksowicz, P.I. \$20,000 from Sandoz Pharmaceuticals
7/1993-6/1996	The Mechanisms of Anti-Tumor Activity of IL-2 and IL-6: The Relationships between the Hemostatic and Immune Systems. Leslie Oleksowicz, P.I. ; \$150,000 from American Cancer Society.
7/1993-6/1996	The Role of IL-6 on Platelet Function. Leslie Oleksowicz, P.I. \$60,000 from Sandoz Pharmaceuticals.
7/1993-6/1996	Research in Platelet Function. Leslie Oleksowicz, P.I. \$25,000 from Irving A Hansen Memorial Foundation.
7/1994-4/1995	Impedance Agregometry Investigating Platelet Tumor Interactions. Leslie Oleksowicz, P.I. , \$30,000 from Carol Solar Abbani Foundation.
7/1994-4/1995	Ex vivo Platelet Functional Studies in Patients with Advanced Breast Carcinoma Who have Undergone Autologous

- Bone Marrow Transplantation and have been Treated with IL-6 or Placebo. **Leslie Oleksowicz, P.I.**; \$30,000 from Sandoz Pharmaceuticals.
- 1/1996-12/1997 Characterization of Immunorelated GPIb Expression by Myelogenous Leukemia Cells. **Leslie Oleksowicz, P.I.**, \$30,000, National Leukemia Research Association.
- 7/1997-7/1998 The Role of Tumor GPIb α in Platelet-Tumor Adhesive Interactions and Metastasis. **Leslie Oleksowicz, P.I.** \$80,000 from the Elsa U. Pardee Foundation.
- 1/1999-1/2001 The Role of GP1b Expressed by Renal Carcinoma Cells in Primary Adhesive Interactions Required for the Metastatic Process. **Leslie Oleksowicz: P.I.**, \$30,000 from the Bruce Cuvelier Endowed Research Fund in Urology.
- 11/1999-10/2000 Tumor Expression of the Immunorelated Platelet Adhesive receptor: GP1b α and α 2 β 3: Novel Targets for Anti-Neoplastic Strategies. **Leslie Oleksowicz: P.I.** \$50,000 from the Roswell Park Alliance Foundation.

Additional Clinical Trials

- 7/1992-7/1993 Co-Investigator: A Compassionate Study of High Dose IL-2 by I.V. Bolus in Patients with Metastatic or unresectable Renal Cell Carcinoma. Investigator-Initiated Trial.
- 5/1992-11/1993 Co-Investigator: A Phase I Study of Interleukin-6 (IL-6, SDZ ILS 969) Administered by 120-Hour Continuous Intravenous Infusion. Sponsored by the Cytokine Working Group and Sandoz Pharmaceuticals
- 8/1993-10/1995 Co-Investigator: Open-Label, Multicenter Trial of Actimmune Interferon Gamma-1b (IFN- γ 1b) in Patients with Metastatic Renal Cell Carcinoma. Sponsored by Genentech.
- 7/1994-8/1995 Co-Investigator: A Phase III Randomized Double Blind, Placebo-Controlled Study of CT-1501R and High Dose Intermittent Interleukin-2 in the Treatment of Patients with Advanced Renal Cell or Metastatic Malignant Melanoma. Sponsored by Cell therapeutics.
- 1/1994-1/1996 Co-investigator: Chemo-Immunotherapy of Metastatic Renal Cell Carcinoma with IL-2, Interferon- α 2b, and 5-FU. Sponsored by the Cytokine Working Group.
- 10/1994-9/1998 Co-Investigator: Randomized Phase II Trial of Chemotherapy and Outpatient Biotherapy in Metastatic Malignant Melanoma. Sponsored by the Cytokine Working Group.
- 6/1996-11/1997 Co-Investigator: A Multicenter Phase II Evaluation of Combination Therapy of Targretin Oral Capsules (LGD 1069) and Intron A in patients with Advanced Renal cell Carcinoma. Sponsored by Ligand Pharmaceuticals and the Schering
- 7/1996-9/1997 Co-Investigator: A Phase II Study of Moderate Dose IL-2 by I.V. Bolus and Subcutaneous GM-CSF in Patients with Metastatic or unresectable Renal Cell Carcinoma. Investigator-initiated study.
- 11/1996-2/1997 Co-Investigator: Open-Label Randomized, Dose-Escalating Study of Recombinant Human Interleukin-12 administered by sub-cutaneous Injection in Patients with Advanced Malignancies. Sponsored by Genetics Institute and Wyeth-Ayerst.
- 7/1997-3/1999 Co-Investigator. A Randomized Phase III Trial of High-Dose IL-2 Versus Subcutaneous Interleukin-2/IFN in Patients with Metastatic Renal Cell Carcinoma. Sponsored by the Cytokine Working Group.
- 5/1997-6/1998 Co-Investigator: Open-Label, Non-Randomized, Dose-Escalating Study of Recombinant Human Interleukin-12 by IV injection in Patients with Untreated or Previously Treated Advanced RCC. Sponsored by Genetics Institute and Wyeth-Ayerst.
- 7/1999-5/2000 A Multi-Center, Escalating dose Phase I Study of IV DENSPM administer daily for 5 days as a Loading dose followed by thrice weekly maintenance dosing for two weeks. Sponsored by Parke-Davis.
- 7/2002-6/2003 Co-Investigator. Phase I Study of Intravenous Tumor Necrosis Factor-alpha Plus Doxorubicin in Patients with Advanced Solid tumors. A Pilot Study.
- 7/2002-6/2003 Co-Investigator. Phase I Study and Pharmacokinetics of Irinotecan in Combination with Fixed Dose Celecoxib in Patients with Advanced Colorectal Cancer. Instituion-sponsered trial.
- 7/2002-6/2003 Co-Investigator. A Phase I Trial of Subcutaneous and Oral Calcitriol (1,25-(OH) $_2$ D $_3$) & Carboplatin in Advanced Solid Tumors. Sponsored by Abbott, Hoffman-LaRoche, CapCURE.
- 2/2003-5/2003 **Principal Investigator.** A Phase II Study of Capecitabine (IND #62761) Plus Gemcitabine for Metastatic Renal Cell Carcinoma. CALGB 9008.
- 5/2002-7/2003 Principal Investigator. Multi-Center Randomized, Controlled, Double-Blind Parallel-Group Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma whose Disease has progressed on Treatment with DTIC, IL-2, IFN α or IFN β . Sponsored by Celgene.
- 9/2003-5/2006 Co-Investigator. Prospective Phase II Clinical Trial: Interferon-alpha, Tamoxifen and Thalidomide for the Treatment of Advanced Renal Cell Carcinoma. Sponsored by Celgene.
- 3/2004-11/2007 Co-Investigator. A Randomized Double Blind, Placebo Controlled Phase III Trial of Immunotherapy with Autologous Antigen-Presenting Cells Loaded with PA2024 (Provenge, APC8015) in Asymptomatic Subjects with Gleason Sum <7, Metastatic Androgen independent Prostate Cancer . Sponsored by Dendreon Corporation.
- 11/2004-2/2006 **Principal Investigator.** Phase II Randomized, Open-Label, Three-Arm, Multicenter Study of Medi-522, A Humanized Monoclonal Antibody Directed against the α v β 3 Integrin, in Combination with Docetaxel, Prednisone and

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.